aTyr Pharma, Inc.

NasdaqCM:ATYR Stock Report

Market Cap: US$73.1m

aTyr Pharma Management

Management criteria checks 2/4

aTyr Pharma's CEO is Sanjay Shukla, appointed in Nov 2017, has a tenure of 8.17 years. total yearly compensation is $1.48M, comprised of 39.2% salary and 60.8% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $109.60K. The average tenure of the management team and the board of directors is 6.8 years and 6.5 years respectively.

Key information

Sanjay Shukla

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage39.24%
CEO tenure8.2yrs
CEO ownership0.1%
Management average tenure6.8yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

Dec 18
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

Will aTyr Pharma (NASDAQ:ATYR) Spend Its Cash Wisely?

Mar 27
Will aTyr Pharma (NASDAQ:ATYR) Spend Its Cash Wisely?

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 09

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Jul 13
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Feb 03
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04
Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04
We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10
We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22
Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25
aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09
Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

CEO Compensation Analysis

How has Sanjay Shukla's remuneration changed compared to aTyr Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$75m

Jun 30 2025n/an/a

-US$67m

Mar 31 2025n/an/a

-US$63m

Dec 31 2024US$1mUS$581k

-US$64m

Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Compensation vs Market: Sanjay's total compensation ($USD1.48M) is above average for companies of similar size in the US market ($USD587.00K).

Compensation vs Earnings: Sanjay's compensation has increased whilst the company is unprofitable.

CEO

Sanjay Shukla (53 yo)

8.2yrs
Tenure
US$1,480,522
Compensation

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Shukla
President8.2yrsUS$1.48m0.15%
$ 109.6k
Jill Broadfoot
Chief Financial Officer7.5yrsUS$746.16k0.032%
$ 23.7k
Nancy E. Krueger
General Counsel & Corporate Secretary11.3yrsUS$729.31k0.027%
$ 19.8k
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno datano datano data
Peter Villiger
Vice President of Corporate Development6yrsno datano data
Danielle Campbell
VP of Human Resource4.1yrsno datano data
Dalia Rayes
Head of Commercialless than a yearno datano data
Leslie Nangle
Vice President of Researchno datano datano data
6.8yrs
Average Tenure
57yo
Average Age

Experienced Management: ATYR's management team is seasoned and experienced (6.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sanjay Shukla
President8.2yrsUS$1.48m0.15%
$ 109.6k
Paul Schimmel
Independent Director20.3yrsUS$70.14k2.14%
$ 1.6m
Eric Benevich
Independent Director1.1yrsUS$227.30k0%
$ 0
Sara Zaknoen
Independent Director4.7yrsUS$80.26k0.0061%
$ 4.5k
Timothy Coughlin
Independent Chairman of the Board8.8yrsUS$129.36k0.057%
$ 41.8k
Susan Ackerman
Member of Scientific Advisory Boardno datano datano data
Jane Gross
Independent Director6.5yrsUS$82.32k0.010%
$ 7.3k
Svetlana Lucas
Independent Director6.5yrsUS$82.26k0.0061%
$ 4.5k
6.5yrs
Average Tenure
60yo
Average Age

Experienced Board: ATYR's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 00:58
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

aTyr Pharma, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Prakhar AgrawalCantor Fitzgerald & Co.
Ilya ZubkovFreedom Broker